Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

chemsolve pty ltd - benzalkonium chloride - pool algicide - swimming pool - algae

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

abbey laboratories pty ltd - ivermectin - topical solution/suspension - ivermectin anthelmintic active 10.0 g/l - parasiticides

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 200 mg - capsule, hard - excipient ingredients: magnesium stearate; erythrosine; pregelatinised maize starch; colloidal anhydrous silica; lactose monohydrate; purified talc; sodium lauryl sulfate; purified water; gelatin; titanium dioxide; brilliant blue fcf - fluconazole, given orally, is indicated for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 150 mg - capsule, hard - excipient ingredients: brilliant blue fcf; pregelatinised maize starch; gelatin; colloidal anhydrous silica; magnesium stearate; sodium lauryl sulfate; purified talc; lactose monohydrate; purified water; titanium dioxide - fluconazole, given orally, is indicated for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 50 mg - capsule, hard - excipient ingredients: purified talc; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; erythrosine; titanium dioxide; lactose monohydrate; brilliant blue fcf; purified water; sodium lauryl sulfate; gelatin - fluconazole, given orally, is indicated for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

ego pharmaceuticals pty ltd - miconazole -

Australia - English - Department of Health (Therapeutic Goods Administration)

ego pharmaceuticals pty ltd - zinc oxide, quantity: 150 mg/g; miconazole, quantity: 2.5 mg/g - ointment - excipient ingredients: white soft paraffin; light liquid paraffin; 1,3-butylene glycol; cetostearyl alcohol; polyethylene; dimeticone 350 - for the treatment of fungal infected nappy rash.

Australia - English - Department of Health (Therapeutic Goods Administration)

ego pharmaceuticals pty ltd - miconazole nitrate, quantity: 20 mg/g - cream - excipient ingredients: phenethyl alcohol; peg-40 stearate; light liquid paraffin; 1,3-butylene glycol; dimeticone 350; cetostearyl alcohol; self-emulsifying glyceryl monostearate; purified water - topical treatment of fungal skin infections, including thrush of the vulval area, male groin area or under breasts, thrush infected napkin rash, tinea (ringworm) of the feet, groin and body, and fungal infections complicated by bacterial infections. for the treatment of seborrhoeic dermatitis, pityriasis versicolor and pityrosporum folliculitis associated with pityrosporum organisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

ego pharmaceuticals pty ltd - miconazole nitrate, quantity: 20 mg/g - powder - excipient ingredients: purified talc; zinc oxide; colloidal anhydrous silica; menthol - topical treatment of fungal infections such as: tinea of the body, feet and hands caused by trichophyton, epidermophyton and microsporum. the following, when associated with pityrosporum organisms: seborrhoeic dermatits, pityrosporum folliculitis and pityriasis versicolor. cutaneous candidiasis and napkin rash.

Australia - English - Department of Health (Therapeutic Goods Administration)

ego pharmaceuticals pty ltd - miconazole nitrate -